Omniscient Raises Series C Funding to Advance AI-Powered Brain Decoding Technology
Omniscent is dedicated to enhancing the potential of the human brain through advanced technology.
Company Name: Omniscent
Location: Sydney, Australia
Sector: Healthcare Technology, Artificial Intelligence
Funding Details: Raised an undisclosed amount in Series C funding, bringing the total investment to US$60M. The round included participation from an undisclosed investor.
Purpose of Investment: To expand its presence in the US market and advance product development efforts for expanded indications.
Leadership: Led by CEO Stephen Scheeler.
Product: Omniscent specializes in connectomics, the AI-driven study of the brain's connectivity. The company’s flagship platform, Quicktome, uses AI to decode and map the brain’s networks from a simple MRI scan, covering functions from motor skills to emotional processing. The platform recently included the first FDA-cleared neurological planning and visualization tool that uses resting-state fMRI, significantly broadening its application in medical fields like stroke, disorders of consciousness, and oncology.
About Company: Omniscent is dedicated to enhancing the potential of the human brain through advanced technology. Its AI-based solutions offer groundbreaking insights into brain functionality, aiding medical professionals in diagnosis and treatment planning. With Quicktome already being utilized in over 100 US hospitals and clinics, the new funding will help Omniscent expand its market reach and continue its innovative work in transforming neurological healthcare.